<DOC>
	<DOCNO>NCT01263938</DOCNO>
	<brief_summary>Activated monocyte play key role pathogenesis HIV-associated neurocognitive disorder ( HAND ) . Individuals HAND expand population activate monocyte . These monocyte think emigrate CNS , produce neurotoxic proinflammatory factor , also carry virus CNS . Statins cholesterol lower drug pleiotropic immunomodulatory / anti-inflammatory property currently explore immunomodulation T cell activation several disease , addition establish role treat hyperlipidemia atherosclerosis . The investigator vitro data suggests drug downregulate monocyte activation pattern see HIV infection . No vivo study yet carry assess effect statins pro-inflammatory monocyte population chronic HIV disease . This pilot study whether statin treatment reduce inflammatory monocyte phenotype downregulate inflammatory cytokine link neuropathogenesis HIV infection . If , may potential adjunctive therapy HIV-associated neurological disease . The investigator propose : - Determine effect Atorvastatin peripheral blood monocyte population 12-week pilot study chronically HIV-infected people HAART therapy . - Determine relationship change monocyte phenotype follow Atorvastatin treatment , soluble marker activation/inflammation link neuropathogenesis , well activation status T cell .</brief_summary>
	<brief_title>Modulation Monocyte Activation Atorvastatin HIV Infection</brief_title>
	<detailed_description />
	<mesh_term>Dementia</mesh_term>
	<mesh_term>AIDS Dementia Complex</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<criteria>1 . Chronic HIV1 infect individual presently HAART change drug combination least 3 month time enrollment 2 . Plasma viral load &lt; 200 copy / ml least 6 month prior enrollment study 3 . CD4 T cell count 350/ul 4 . Willingness use method contraception study period 5 . Willingness blood draw 6 . If female , willingness undergo pregnancy test monthly basis breastfeed 7 . Ability understand willingness sign inform consent 8. hsCRP level upper limit normal ( &gt; 3mg/L ) 1 . Concomitant use fibric acid derivative lipid lower agent include patient statins Ezetimibe 2 . Use antiinflammatory drug ( OTC prescription ) daily basis 3 . Pregnancy breast feed 4 . Active drug use alcohol abuse/dependence , opinion investigator interfere patient 's ability participate study 5 . Allergy hypersensitivity statins component 6 . History myositis rhabdomyolysis use statins 7 . Patients concurrent immunomodulatory agent , include systemic corticosteroid ineligible 3 month completion therapy immunomodulating agent 8 . History inflammatory muscle disease poly dermatomyositis 9 . Serious intercurrent illness require systemic treatment and/or hospitalization within 30 day entry 10 . Evidence active opportunistic infection require treatment neoplasm require chemotherapy study period 11 . Creatine phosphokinase elevation ( CPK ) great 3 time upper limit normal 12 . Known active liver disease AST/ALT great 2x upper limit normal 13 . Renal insufficiency , indicate serum creatinine 2 mg/dl 14 . Absolute neutrophil count ( ANC ) 1000/mm3 , hemoglobin &lt; 10.0 g/dL male &lt; 9 g/dL female , platelet count 100,000/mm</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>HIV</keyword>
	<keyword>monocyte</keyword>
	<keyword>CD16+</keyword>
	<keyword>statin</keyword>
	<keyword>mcp1</keyword>
	<keyword>inflammation</keyword>
</DOC>